TRISCEND II Pivotal Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 864 participants.
Also called NCT04482062
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 864 participants
- Sponsor
- Registry
-
NCT04482062
-
- Other papers using this trial's data
- TRISCEND II: Effect of Transcatheter Tricuspid Valve Replacement on Echocardiographic Measures of Right Heart Remodeling and Function
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Germany
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04482062. Randomized; no masking; primary purpose treatment. Start 2021-04-09 (actual); primary completion 2025-12-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TRISCEND II Pivotal Trial
- Condition
- Tricuspid Valve Regurgitation
- Condition
- Tricuspid Valve Insufficiency
- Condition
- Tricuspid Valve Disease
- Condition
- Heart Valve Diseases
- Condition
- Cardiovascular Diseases
- Condition
- Heart Failure
- Intervention (Device)
- Edwards EVOQUE System
- Intervention (Drug)
- Optimal Medical Therapy
- Lead sponsor
- Edwards Lifesciences
Record details
- Record id
cardio:ct-nct04482062- Content hash
bd653d362f11d1230851bcc09057d5194df114a0da71b8294a7f29cfcfcf0279